Edition:
United Kingdom

Seikagaku Corp (4548.T)

4548.T on Tokyo Stock Exchange

1,421JPY
13 Jul 2018
Change (% chg)

¥5 (+0.35%)
Prev Close
¥1,416
Open
¥1,429
Day's High
¥1,439
Day's Low
¥1,417
Volume
74,200
Avg. Vol
127,115
52-wk High
¥2,236
52-wk Low
¥1,383

Latest Key Developments (Source: Significant Developments)

Seikagaku initiates a phase III clinical trial (additional study) in the U.S. for SI-6603
Monday, 19 Feb 2018 

Feb 19 (Reuters) - Seikagaku Corp <4548.T>:Says it will initiate a Phase III clinical trial (additional study) in the U.S. for SI-6603, indicated for the treatment of radicular leg pain (i.e. sciatica) due to a lumbar disc herniation. .  Full Article

Ribomic signs collaborative research contract with SEIKAGAKU
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Ribomic Inc <4591.T>:Says it signed collaborative research contract with SEIKAGAKU CORPORATION <<<4548.T>>>.Says two entities mainly cooperate on new technologies development of drug discovery related to Aptamers.  Full Article

Seikagaku signs exclusive worldwide license agreement for treatment for lumbar disc herniation
Monday, 29 Aug 2016 

Seikagaku Corporation <4548.T>: Says the co entered into an exclusive worldwide license agreement(excluding Japan) with Ferring Pharmaceuticals for SI-6603(condoliase), a potential treatment for lumbar disc herniation .Says the co will receive an upfront payment of $5 million and milestone payments up to a maximum total amount of $90 million over multiple years upon future progress in development and commercialization.  Full Article

BRIEF-Seikagaku announces new drug application approval of hernicore® 1.25 units for intradiscal injection in Japan

* Says it announced that the Japanese Ministry of Health, Labour and Welfare has approved the new drug application of HERNICORE® 1.25 units for intradiscal injection in Japan, indicated for the treatment of lumbar disc herniation